Transition Therapeutics Overview

  • Year Founded
  • 1987

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 18

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $58.5M

Transition Therapeutics General Information

Description

Developer of therapeutics for disease indications. The company provides a product for the treatment of Alzheimer's disease and for the treatment of diabetes.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 101 College Street
  • Suite 220
  • Toronto, Ontario M5G 1L7
  • Canada
Primary Industry
Drug Discovery
Acquirer
Vertical(s)
Corporate Office
  • 101 College Street
  • Suite 220
  • Toronto, Ontario M5G 1L7
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Transition Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 31-Aug-2016 $58.5M Completed Generating Revenue
4. PIPE 23-Jun-2014 Completed Generating Revenue
3. PIPE 02-Aug-2013 Completed Generating Revenue
2. PIPE $3.28M Completed Generating Revenue
1. IPO 28-Feb-2001 $3.28M $3.28M Completed Generating Revenue
To view Transition Therapeutics’s complete valuation and funding history, request access »

Transition Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutics for disease indications. The company provides a product for the treatment of Alzheimer's disea
Drug Discovery
Toronto, Canada
18 As of 2015

Lexington, MA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Transition Therapeutics Competitors (54)

One of Transition Therapeutics’s 54 competitors is Voyager Therapeutics, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Voyager Therapeutics Formerly VC-backed Lexington, MA
Vertex Pharmaceuticals Formerly VC-backed Boston, MA
uniQure Formerly VC-backed Amsterdam, Netherlands
Minerva Neurosciences Formerly VC-backed Burlington, MA
Sangamo Therapeutics Formerly VC-backed Richmond, CA
You’re viewing 5 of 54 competitors. Get the full list »

Transition Therapeutics Patents

Transition Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2008083280-A1 Compounds and methods of treating insulin resistance and cardiomyopathy Inactive 29-Dec-2006
US-20080139455-A1 (2s,3s,e)-2-amino-14,14-difluoro-3-hydroxytetradec-6-enoic acid; serine palmitoyl transferase ; insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia Inactive 12-Oct-2006
WO-2008046071-A2 Compounds and methods of treating metabolic syndrome and inflammation Inactive 12-Oct-2006
WO-2008043102-A2 Vasoactive intestinal polypeptide compositions Inactive 06-Oct-2006
WO-2008031032-A2 Compounds for and methods of treating insulin resistance and inflammation Inactive 07-Sep-2006 C07C229/36
To view Transition Therapeutics’s complete patent history, request access »

Transition Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Transition Therapeutics Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Oracle Investment Management Hedge Fund Minority
To view Transition Therapeutics’s complete investors history, request access »

Transition Therapeutics Acquisitions (1)

Transition Therapeutics’s most recent deal was a Merger/Acquisition with NeuroMedix for . The deal was made on 01-Jun-2007.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
NeuroMedix 01-Jun-2007 Merger/Acquisition Drug Discovery
To view Transition Therapeutics’s complete acquisitions history, request access »

Transition Therapeutics FAQs

  • When was Transition Therapeutics founded?

    Transition Therapeutics was founded in 1987.

  • Where is Transition Therapeutics headquartered?

    Transition Therapeutics is headquartered in Toronto, Canada.

  • What is the size of Transition Therapeutics?

    Transition Therapeutics has 18 total employees.

  • What industry is Transition Therapeutics in?

    Transition Therapeutics’s primary industry is Drug Discovery.

  • Is Transition Therapeutics a private or public company?

    Transition Therapeutics is a Private company.

  • What is the current valuation of Transition Therapeutics?

    The current valuation of Transition Therapeutics is .

  • What is Transition Therapeutics’s current revenue?

    The current revenue for Transition Therapeutics is .

  • How much funding has Transition Therapeutics raised over time?

    Transition Therapeutics has raised $55.8M.

  • Who are Transition Therapeutics’s investors?

    Oracle Investment Management has invested in Transition Therapeutics.

  • Who are Transition Therapeutics’s competitors?

    Voyager Therapeutics, Vertex Pharmaceuticals, uniQure, Minerva Neurosciences, and Sangamo Therapeutics are some of the 54 competitors of Transition Therapeutics.

  • When was Transition Therapeutics acquired?

    Transition Therapeutics was acquired on 31-Aug-2016.

  • Who acquired Transition Therapeutics?

    Transition Therapeutics was acquired by OPKO Health.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process